Cargando…

Profile of ceritinib in the treatment of ALK+ metastatic non-small-cell lung cancer

Lung cancer has become one of the leading causes of death in both men and women in the United States, with approximately 230,000 new cases and 160,000 deaths each year. Approximately 80% of lung cancer patients are diagnosed with non-small-cell lung cancer (NSCLC), a subset of epithelial lung cancer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burns, Mark W, Kim, Eric S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217515/ https://www.ncbi.nlm.nih.gov/pubmed/28210149 http://dx.doi.org/10.2147/LCTT.S69114

Ejemplares similares

Ceritinib for ALK-Rearrangement–Positive Non–Small Cell Lung Cancer
por: Nix, Nancy M., et al.
Publicado: (2015)

Personalized treatment options for ALK-positive metastatic non-small-cell lung cancer: potential role for Ceritinib
por: El-Osta, Hazem, et al.
Publicado: (2015)

New treatment options for ALK+ advanced non-small-cell lung cancer: critical appraisal of ceritinib
por: Rothschild, Sacha I
Publicado: (2016)

Successful rechallenge with ceritinib after leukocytoclastic vasculitis during ceritinib treatment for non-small cell lung cancer harboring the EML4-ALK fusion protein
por: Okimoto, Tamio, et al.
Publicado: (2018)

Novel targeted therapies for resistant ALK-rearranged non-small-cell lung cancer: ceritinib and beyond
por: Kanaan, Zeyad, et al.
Publicado: (2015)

Real-life experience of ceritinib in crizotinib-pretreated ALK(+) advanced non-small cell lung cancer patients
por: Cadranel, Jacques, et al.
Publicado: (2018)

Ceritinib Aggravates Glycemic Control in Insulin-treated Patients with Diabetes and Metastatic ALK-positive Lung Cancer
por: Sakuma, Ikki, et al.
Publicado: (2018)

Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non–Small Cell Lung Cancer Cells
por: Dong, Xuyuan, et al.
Publicado: (2016)

Proactive management strategies for potential gastrointestinal adverse reactions with ceritinib in patients with advanced ALK-positive non-small-cell lung cancer
por: Schaefer, Eric S, et al.
Publicado: (2016)

Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer
por: Won, Brian, et al.
Publicado: (2016)

A case of ALK-rearranged non–small cell lung cancer that responded to ceritinib after development of resistance to alectinib
por: Makuuchi, Yosuke, et al.
Publicado: (2018)

Efficacy of Crizotinib, Ceritinib, and Alectinib in ALK-Positive Non-Small Cell Lung Cancer Treatment: A Meta-Analysis of Clinical Trials
por: Hoang, Tung, et al.
Publicado: (2020)

Assessment of Alectinib vs Ceritinib in ALK-Positive Non–Small Cell Lung Cancer in Phase 2 Trials and in Real-world Data
por: Wilkinson, Samantha, et al.
Publicado: (2021)

Crizotinib resistance overcome by ceritinib in an ALK-positive non-small cell lung cancer patient with brain metastases: A case report
por: Zhu, Zhouyu, et al.
Publicado: (2017)

Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy
por: Santarpia, Mariacarmela, et al.
Publicado: (2017)

Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib
por: van Erp, Anke E. M., et al.
Publicado: (2017)

Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib
por: Guan, Jikui, et al.
Publicado: (2018)

The ALK inhibitors, alectinib and ceritinib, induce ALK‐independent and STAT3‐dependent glioblastoma cell death
por: Kawauchi, Daisuke, et al.
Publicado: (2021)

ALK‐rearranged lung cancer with intradural extramedullary spinal cord metastases responding to ceritinib treatment: A case report
por: Xu, Yan, et al.
Publicado: (2018)

Organizing pneumonia in ALK+ lung adenocarcinoma treated with ceritinib: A case report and literature review
por: Wu, Yonghui, et al.
Publicado: (2021)

STRN-ALK Rearranged Malignant Peritoneal Mesothelioma With Dramatic Response Following Ceritinib Treatment
por: Rüschoff, Jan H., et al.
Publicado: (2019)

Pulmonary granulomatous inflammation after ceritinib treatment in advanced ALK-rearranged pulmonary adenocarcinoma
por: Liao, Juanyan, et al.
Publicado: (2022)

Ceritinib in Japanese patients with anaplastic lymphoma kinase (ALK)+ non-small cell lung cancer: interim analysis results of a post-marketing surveillance study
por: Kaneda, Hiroyasu, et al.
Publicado: (2020)

Pathological complete response to neoadjuvant ceritinib of a crizotinib‐resistant, stage IIIB non‐small cell lung cancer with ALK rearrangement: A case report
por: Bing, Zhongxing, et al.
Publicado: (2021)

Afatinib reverses ceritinib resistance (CR) in ALK/ROS1-positive non-small-cell lung cancer cell (NSCLC) via suppression of NRG1 pathway
por: Chen, Hui, et al.
Publicado: (2018)

Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong
por: Loong, Herbert H., et al.
Publicado: (2020)

Neoadjuvant ceritinib treatment in ALK ‐rearranged locally advanced adenosquamous carcinoma: A case report
por: Mai, Shixiong, et al.
Publicado: (2022)

Intracranial and whole-body response of ceritinib in ALK inhibitor-naïve and previously ALK inhibitor-treated patients with ALK-rearranged non-small-cell lung cancer (NSCLC): updated results from the phase 1, multicentre, open-label ASCEND-1 trial
por: Kim, Dong-Wan, et al.
Publicado: (2016)

Successful ceritinib treatment in a man with MPE and an ALK fusion gene mutation after multiple treatments
por: Wei, Hangping, et al.
Publicado: (2016)

ALK Rearrangement Adenocarcinoma with Histological Transformation to Squamous Cell Carcinoma Resistant to Alectinib and Ceritinib
por: Kaiho, Taisuke, et al.
Publicado: (2020)

Correction to “Neoadjuvant ceritinib treatment in ALK ‐rearranged locally advanced adenosquamous carcinoma: A case report”
Publicado: (2023)

Activity of ceritinib in crizotinib-resistant ROS1-rearranged non-small-cell lung cancer patients
por: Zhang, Huixian, et al.
Publicado: (2023)

Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma
por: Subbiah, V., et al.
Publicado: (2021)

Identification of a novel RMST-ALK rearrangement in advanced lung adenocarcinoma and durable response to ceritinib: A case report
por: Li, Hui, et al.
Publicado: (2022)

Phase II study of ceritinib in alectinib‐pretreated patients with anaplastic lymphoma kinase‐rearranged metastatic non‐small‐cell lung cancer in Japan: ASCEND‐9
por: Hida, Toyoaki, et al.
Publicado: (2018)

P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer
por: Katayama, Ryohei, et al.
Publicado: (2015)

Response to a Combination of Full-Dose Osimertinib and Ceritinib in a Non-Small Cell Lung Cancer Patient with EML4-ALK Rearrangement and Epidermal Growth Factor Receptor Co-Mutation
por: Nguyen, Thai Hoa Thi, et al.
Publicado: (2021)

New options in the management of intractable ALK(+) metastatic non-small-cell lung cancer
por: Weise, Amy M, et al.
Publicado: (2014)

Efficacy and Safety of Ceritinib 450 mg/day with Food and 750 mg/day in Fasted State in Treatment-Naïve Patients with ALK+ Non–Small Cell Lung Cancer: Results from the ASCEND-8 Asian Subgroup Analysis
por: Cho, Byoung Chul, et al.
Publicado: (2023)

ET-05 Alectinib and ceritinib, the second-generation ALK inhibitors, effectively induce glioblastoma cell death
por: Kawauchi, Daisuke, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5ed5d5iscrdmfjd69l3nbchuq9